The role of the endogenous opioid system in polycystic ovary syndrome

Fertility and Sterility

Volumn 92, Issue 1, 2009, Pages 1-12

  Eyvazzadeh, Aimee D ^a   Pennington, Kathryn P ^a   Pop Busui, Rodica ^a   Sowers, MaryFran ^a   Zubieta, Jon Kar ^a,b   Smith, Yolanda R ^a  

^a Section on Statistical Genetics   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

beta endorphin; insulin resistance; naloxone; Naltrexone; PCOS

Indexed keywords

ALPHA INTERMEDIN; BETA ENDORPHIN; BETA INTERMEDIN; CLOMIFENE CITRATE; DELTA OPIATE RECEPTOR; ENDORPHIN; FLUTAMIDE; GAMMA INTERMEDIN; GAMMA LIPOTROPIN; GONADORELIN; KAPPA OPIATE RECEPTOR; METFORMIN; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PIOGLITAZONE; SEX HORMONE;

ARTICLE; CARBOHYDRATE METABOLISM; CENTRAL NERVOUS SYSTEM FUNCTION; COGNITION; DEPRESSION; ENZYME REGULATION; FEMALE; FEMALE INFERTILITY; HUMAN; HYPERINSULINEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFERTILITY THERAPY; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN RESISTANCE; LIMBIC CORTEX; METABOLIC REGULATION; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PANCREAS CELL; PANCREAS FUNCTION; PERIPHERAL NERVOUS SYSTEM FUNCTION; PRIORITY JOURNAL; REGULATORY MECHANISM; REPRODUCTION; STRESS;

ANALGESICS, OPIOID; BRAIN; COGNITION; DEPRESSION; FEMALE; HUMANS; INFERTILITY, FEMALE; POLYCYSTIC OVARY SYNDROME; RECEPTORS, OPIOID, MU; REPRODUCTION; STRESS, PSYCHOLOGICAL;

EID: 67649103570     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.05.012     Document Type: Article

References (182)

1. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol 31 (1989) 87-120
2. Sharma S.T., and Nesler J.E. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers. Best Practice Res Clin Endocrinol Metab 20 (2006) 245-260
3. Goldzieher J.W. Polycystic ovarian disease. Fertil Steril 35 (1981) 371-394
4. Zawadslo J.K., and Dunaif A. Diagnostic criteria for polycystic ovary syndrome (PCOS): towards a rational approach. In: Dunaif A., Givens J.R., Haseltine F.P., et al. (Eds). Current issues in endocrinology and metabolism: polycystic ovary syndrome (1992), Blackwell, Boston 377
5. Conway G.S., Honour J.W., and Jacobs H.S. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine, and ultrasound features in 556 patients. Clin Endocrinol 30 (1989) 459-470
6. Carmina E., Koyama T., Chang L., Stanczyk F.Z., and Lobo R.A. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. Am J Obstet Gynecol 167 (1992) 1807-1812
7. Legro R.S., Kunselman A.R., Dodson W.C., and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
8. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 1005;83:1454-60.
9. Solomon C.G. Reducing cardiovascular risk in type 2 diabetes. N Engl J Med 348 (2003) 457-459
10. Ehrmann D.A., Barnes R.B., Rosenfield R.L., Cavaghan M.K., and Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 (1999) 141-146
11. Glueck C.J., Papanna R., Wang P., Goldenberg N., and Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52 (2003) 908-915
12. Apridonidze T., Essah P.A., Iuorno M.J., and Nestler J.E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 1929-1935
13. Sam S., Legro R.S., Bentley-Lewis R., and Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 4797-4802
14. Yen S.S.C., Vela P., and Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease, hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 30 (1970) 435-442
15. Marshall J.C., and Eagleson C.A. Neuroendocrine aspects of polycystic ovary syndrome. Endocrinol Metab Clin North Am 28 (1999) 295-324
16. Solomon C.G. The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metab Clin North Am 28 (1999) 247-263
17. Nelson V.L., Qin K.N., Rosenfield R.L., Wood J.R., Penning T.M., Legro R.S., et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 86 (2001) 5925-5933
18. Dunaif A., Segal K.R., Futterweit W., and Dobtiansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
19. Gambineri A., Pelusi C., Vicennati V., Pagotto U., and Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 26 (2002) 883-896
20. Taksali S.E., Caprio S., Dziura J., Dufour S., Calí A.M., Goodman T.R., et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes 57 (2008) 367-371
21. Dunaif A., Wu X., Lee A., and Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 281 (2001) E392-E399
22. Book C.B., and Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. Clin Endocrinol Metab 84 (1999) 3110-3116
23. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril 86 Suppl 1 (2006) S13-S14
24. Lanzone A., Fulghesu A.M., Fortini A., Cutillo G., Cucinelli F., Di Simone N., et al. Effect of opiate receptorvblockade on the insulin response to oral glucose load in polycystic ovarian disease. Hum Reprod 6 (1991) 1043-1049
25. Fulghesu A.M., Lanzone A., Cucinelli F., Caruso A., and Mancuso S. Long-term naltrexone treatment reduces the exaggerated insulin secretion in patients with polycystic ovary disease. Obstet Gynecol 82 (1993) 191-197
26. Lanzone A., Apa R., Fulghesu A.M., Cutillo G., Caruso A., and Mancuso S. Long-term naltrexone treatment normalizes the pituitary response to gonadotropin-releasing hormone in polycystic ovarian syndrome. Fertil Steril 59 (1993) 734-737
27. Barnes R.B., and Lobo R.A. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation. J Clin Endorcinol Metab 61 (1985) 779-782
28. Cumming D.C., Reid R.L., Quigley M.E., Rebar R.W., and Yen S.S. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome. Clin Endorinol 20 (1984) 643-648
29. Guido M., Romualdi D., and Lanzone A. Role of opioid antagonists in the treatment of women with glucoregulation abnormalities. Curr Pharmaceutical Design 12 (2006) 1001-1012
30. Lackey B.R., Gray S.L., and Henricks D.M. The insulin-like growth factor (IGF) system and gonadotropin regulation: actions and interactions. Cytokine Growth Factor Rev 10 (1999) 201-217
31. Snowden E.U., Khan-Dawood F.S., and Dawood M.Y. The effect of naloxone on endogenous opioid regulation of pituitary gonadotrophins and prolactin during the menstrual cycle. J Clin Endocrinol Metab 59 (1984) 298-302
32. Pang C.N., Zimmerman E., and Sawyer C.M. Morphine inhibition of the preovulatory surges of plasma LH/FSH in the rat. Endocrinology 101 (1977) 1726-1732
33. Piva F., Limonta P., Dondi D., Pimpinelli F., Martini L., and Maggi R. Effects of steroids on the brain opioid system. J Steroid Biochem Mol Biol 53 (1995) 343-348
34. Piva F., Limonta P., Maggi R., and Martini L. Stimulatory and inhibitory effects of the opioids on gonadotropin secretion. Neuroendocrinology 42 (1986) 504-512
35. Gabriel S.M., Berglund L.A., and Simpkins J.W. A decline in endogenous opioid influence during the steroid-induced hypersecretion of luteinizing hormone in the rat. Endocrinology 118 (1986) 558-561
36. Giugliano D., Ceriello A., Salvatore T., Paolisso G., D'Onofrio F., and Lefebvre P.J. β-Endorphin infusion restores acute insulin response to glucose in type-II diabetes mellitus. J Clin Endocrinol Metab 64 (1978) 944-948
37. Wortsman J., Wehrenberg W.B., Gavin J.R., and Allen J.P. Elevated levels of plasma beta-endorphin and melanocyte stimulating hormone in the polycystic ovary syndrome. Obstet Gynecol 63 (1984) 630-635
38. Fulghesu A.M., Ciampelli M., Belosi C., Apa R., Guido M., Caruso A., et al. Naltrexone effects on pulsatile GnRH therapy for ovulation induction in PCOS: a pilot prospective study. J Endocrinol Invest 24 (2001) 483-490
39. Fulghesu A.M., Lanzone A., Cucinelli F., Caruso A., and Mancuso S. Long-term naltrexone treatment reduces the exaggerated insulinsecretion in patients with polycystic ovary disease. Obstet Gynecol 82 (1993) 191-197
40. Smith Y.R., Stohler C.S., Nichols T.E., Bueller J.A., Koeppe R.A., and Zubieta J.K. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci 26 (2006) 5777-5785
41. Drolet G., Dumont E.C., Gosselin I., Kinkead R., Laforest S., and Trottier J.F. Role of endogenous opioid system in the regulation of the stress response. Prog Neurosychopharmacol Biol Psychiatry 25 (2001) 729-741
42. Watkins L., and Mayer D. Organization of endogenous opiate and nonopiate pain control systems. Science 216 (1982) 1185-1192
43. Rubinstein M., Mogil J.S., Japon M., Chan E.C., Allen R.G., and Low M.J. Absence of opioid stress-induced analgesia in mice lacking β-endorphin by site directed mutagenesis. Proc Natl Acad Sci USA 93 (1996) 3995-4000
44. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., et al. Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94 (1997) 1544-1549
45. Zubieta J.K., Smith Y., Bueller J., Xu Y., Kilbourn M., Meyer C., et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 293 (2001) 311-315
46. Fadda P., Tortorella A., and Fratta W. Sleep deprivation decreases mu and delta opioid receptor binding in the rat limbic system. Neurosci Lett 129 (1991) 315-317
47. Guillemin R., Vargo T., Rossier J., Minick S., Ling N., Rivier C., et al. Beta-endorphin and adrenocorticotropin are secreted concomitantly by the pituitary gland. Science 197 (1977) 1367-1369
48. Panksepp J. Feeling the pain of social loss. Science 302 (2003) 237-239
49. Kennedy S.E., Koeppe R.A., Young E.A., and Zubieta J.K. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 63 (2006) 1199-1208
50. Lembo P.M.C., Grazzini E., Groblewski T., O'Donnell D., Roy M.O., Zhang J., et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat Neurosci 5 (2002) 201-209
51. Hong Y., Dai P., Jiang J., and Zeng X. Dual effects of intrathecal BAM22 on nociceptive responses in acute and persistent pain-potential function of a novel receptor. Br J Pharmacol 141 (2004) 423-440
52. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.F. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 97 (1976) 517-532
53. Lord J.A., Waterfield A.A., Hughes J., and Kosterlitz H.W. Endogenous opioid peptides: multiple agonists and receptors. Nature 267 (1977) 495-499
54. Bunzow J.R., Saez C., Mortrud M., Bouvier C., Williams J.T., Low M., et al. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett 347 (1994) 284-288
55. Chen Y., Fan Y., Liu J., Mestek A., Tian M., Kozac C.A., et al. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett 347 (1994) 279-283
56. Fukuda L., Kato S., Mori K., Nishi M., Takeshima H., Iwabe N., et al. cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett 343 (1994) 42-46
57. Mollereau C., Parmentier M., Mailleux P., Butour J.L., Moisand C., Chalon P., et al. ORL-1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 341 (1994) 33-38
58. Wang J.B., Johnson P.S., Imai Y., Persico A.M., Ozenberger B.A., Eppler C.M., et al. cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett 348 (1994) 75-79
59. Wick M.J., Minnerath S.R., Lin X., Elde R., Law P.Y., and Loh H.H. Isolation of a novel cDNA encoding a putative membrane receptor with high homology to the cloned mu, delta, and kappa opioid receptors. Brain Res Mol Brain Res 27 (1994) 37-44
60. Lachowicz J.E., Shen Y., F.Monsma F.J., and Sibley D.R. Molecular cloning of a novel G protein-coupled receptor related to the opiate receptor family. J Neurochem 64 (1995) 34-40
61. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., and Hamon M. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 48 (1996) 567-592
62. Hughes J., Smith T.W., Kosterlitz H.W., Fothergill L.A., Morgan B.A., and Morri H.R. Identification of two related pentapeptides from the brain with potent opiate agonistic activity. Nature 258 (1975) 577-580
63. Bradbury A.F., Smyth D.G., and Snell C.R. Biosynthetic origin and receptor conformation of methionine enkephalin. Nature 260 (1976) 165-166
64. Goldstein A., Fischli W., Lowney L.I., Hunkapiller M., and Hood L. Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptide. Proc Natl Acad Sci USA 78 (1981) 7219-7223
65. Zadina J.E., Hackler L., Ge L.J., and Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 (1997) 502-505
66. Meunier J.C., Mollereau C., Toll L., Saudeau C., Moisand C., Alvinerie P., et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532
67. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995) 792-794
68. Nakanishi S., Inoue A., Kita T., Nakamura M., Chang A.C., Cohen S.N., et al. Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature 278 (1979) 423-427
69. Noda M., Furutani Y., Takahashi H., Toyosato M., Hirose T., Inayama S., et al. Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature 295 (1982) 202-206
70. Kakidani H., Furutani Y., Takahashi H., Noda M., Morimoto Y., Hirose T., et al. Cloning and sequence analysis of cDNA for porcine beta-neo-endorphin/dynorphin precursor. Nature 298 (1982) 245-249
71. Nothacker H.P., Reinscheid R.K., Mansour A., Henningsen R.A., Ardati A., Monsma F.J., et al. Primary structure and tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci USA 93 (1996) 8677-8682
72. Pan Y.X., Xu J., and Pasternak G.W. Cloning and expression of a cDNA encoding a mouse brain orphanin FQ/nociceptin precursor. Biochem. J 315 (1996) 11-13
73. Corbett A.D., Paterson S.J., and Kosterlitz H.W. Selectivity of ligands for opioid receptors. In: Herz A. (Ed). Handbook of experimental pharmacology. Opioids 1 (1993), Springer, New York 645-649
74. Gutstein H.B., and Akil H. Opioid analgesics. In: Hardman J.G., Limbird L.E., and Goodman-Gilman A. (Eds). The pharmacological basis of therapeutics (2001), McGraw-Hill, New York 569-619
75. Bodnar R.J., and Hadjimarkou M.M. Endogenous opiates and behavior: 2001. Peptides 23 (2002) 2307-2365
76. Zubieta J.K., Smith Y., Bueller J., Xu Y., Woike T., Kilbourn M., et al. Mu-opioid receptor mediated antinociception differs in men and women. J Neurosci 22 (2002) 5100-5107
77. Gear R., Miaskowski C., Gordon N., Paul S., Heller P., and Levine J. Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med 2 (1996) 1248-1250
78. Mogil J.S., Wilson S.G., Chesler E.J., Rankin A.L., Nemmani K.V., Lariviere W.R., et al. The melanocortin-1 receptor gene mediates female specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA 100 (2003) 4867-4872
79. Williams K.L., Ko M.C., Rice K.C., and Woods J.H. Effect of opioid receptor antagonists on hypothalamic-pituitary-adrenal activity in rhesus monkeys. Psychoneuroendocrinology 28 (2003) 513-528
80. Jutkiewicz E.M., Rice K.C., Woods J.H., and Winsauer P.J. Effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats. Behav Pharmacol 14 (2003) 509-516
81. Torregrossa M.M., Isgor C., Folk J.E., Rice K.C., Watson S.J., and Woods J.H. The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology 29 (2004) 649-659
82. Wang Z., Gardell L.R., Ossipov M.H., Vanderah T.W., Brennan M.B., Hochgeschwender U., et al. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci 21 (2001) 1779-1786
83. Sugita S., and North R.A. Opioid actions on neurons of rat lateral amygdala in vitro. Brain Res 612 (1993) 151-155
84. Childers S.R. Opioid receptor-coupled second messenger systems. Life Sci 48 (1991) 1991-2003
85. Acosta-Martinez M., and Etgen A.M. Estrogen modulation of mu-opioid receptor-stimulated [35S]-GTP-gamma-S binding in female rat brain visualized by in vitro autoradiography. Neuroendocrinology 76 (2002) 235-242
86. Grossman A., Moult P.J., Gaillard R.C., Delitalah G., Toff W., Rees L., et al. The opioid control of LH and FSH release: effects of a metenkephalin analogue and naloxone. Clin Endocrinol 14 (1981) 41-47
87. Quigley M.E., and Yen S.S. The role of endogenous opiates on LH secretion during the menstrual cycle. J Clin Endocrinol Metab 51 (1980) 179-180
88. Blankstein J., Reyes F., Winter J.S., and Faiman C. Endorphins and the regulation of the human menstrual cycle. Clin Endocrinol 14 (1981) 287
89. Santen R.J., Sofsky J., Bilic N., and Lippert R. Mechanism of action of narcotics in the production of menstrual dysfunction in women. Fertil Steril 26 (1975) 538
90. Wehrenberg W.B., Wardlaw S.L., Frantz A.G., and Ferin M. beta-Endorphin in hypophyseal portal blood: variations throughout the menstrual cycle. Endocrinology 111 (1982) 879-881
91. Rossmanith W.G., and Yen S.S. Sleep-associated decrease in luteinizing hormone pulse frequency during the early follicular phase of the menstrual cycle: evidence for an opioidergic mechanism. J Clin Endocrinol Metab 65 (1987) 715-718
92. Kalra S.P. Neural loci involved in naloxone-induced luteinizing hormone release: effects of a norepinephrine synthesis inhibitor. Endocrinology 109 (1981) 1805-1810
93. Leadem C.A., and Yagenova S.V. Effects of specific activation of μ-, δ- and κ-opioid receptors on the secretion of luteinizing hormone and prolactin in the ovariectomized rat. Neuroendocrinology 45 (1987) 109-117
94. Olster D.H. Site-specific opioid receptor blockade allows prepubertal guinea pigs to display progesterone-facilitated lordosis. Horm Behav 33 (1998) 115-124
95. Wardlaw S.L., Wehrenberg W.B., Ferin M., Antunes J.L., and Frantz A.G. Effect of sex steroids on beta-endorphin in hypophyseal portal blood. J Clin Endocrinol Metab 55 (1982) 877-881
96. Petersen S.L., and LaFlamme K.D. Progesterone increases levels of mu-opioid receptor mRNA in the preoptic area and arcuate nucleus of ovariectomized, estradiol-treated female rats. Brain Res Mol Brain Res 52 (1997) 32-37
97. Ipp E., Dobbs R., and Unger R.H. Morphine and beta-endorphin influence the secretion of the endocrine pancreas. Nature 276 (1978) 190-191
98. Givens J.R., Widerman E., Anderson R.N., and Labchi A.E. B-Endorphin and B-lipotropin plasma levels in hirsute women: correlation with body weight. J Clin Endocrinol Metab 50 (1980) 975-976
99. Aleem F.A., and McIntosh T. Elevated plasma levels of B-endorphin in a group of women with polycystic ovarian disease. Fertil Steril 42 (1984) 686
100. Wortsman J., Wehrenberg W.B., Gavin J.R., and Allen J.P. Elevated levels of plasma beta-endorphin and melanocyte stimulating hormone in the polycystic ovary syndrome. Obstet Gynecol 63 (1984) 630-635
101. Giugliano D., Salvatore T., Cozzolino D., Ceriello A., and Torella R. D'Onofrio. Sensitivity to beta-endorphin as a cause of human obesity. Metabolism 36 (1987) 974-978
102. Reid R.L., and Yen S.S.C. Beta-endorphin stimulates the secretion of insulin and glucagon in humans. J Clin Endocrinol Metab 52 (1981) 592-594
103. Feldman M., Kiser R.S., Unger R.H., and Li C.H. Beta endorphin and the endocrine pancreas. Studies in healthy and diabetic human beings. New Engl J Med 308 (1983) 349-353
104. Laatikainen T., Salminen K., Virtanen T., and Apter D. Plasma b-endorphin, b-lipotropin and corticotropin in polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 24 (1987) 237-243
105. Hashiguchi Y., Molina P.E., Fan J., Lang C.H., and Abumrad N.N. Central opiate modulation of growth hormone and insulin-like growth factor-I. Brain Res Bull 40 (1996) 99-104
106. Maison P., Balkau B., Souberbielle J.C., Cunin P., Vol S., Macquin-Mavier I., et al. Evidence for distinct effects of GH and IGF-I in the metabolic syndrome. Diabet Med 24 (2007) 1012-1018
107. Unger J.W., and Lange W. Insulin receptors in the pituitary gland: morphological evidence for influence on opioid peptide-synthesizing cells. Cell Tissue Res 288 (1997) 471-483
108. Ramabadran K., and Bansinath M. Glucose homeostasis and endogenous opioid peptides. Int J Clin Pharmacol Ther Toxicol 28 (1990) 89-98
109. Ritter M.M., Mohrle W., Richter W.O., and Schwandt P. No change of beta-endorphin plasma levels during hyperglicemic glucose clamping in obese patients and lean controls. Horm Metab Res 22 (1990) 504-505
110. Pasquali R., Cantobelli S., Casimirri F., Bortoluzzi L., Boschi S., Capelli M., et al. The role of the opioid peptides in the development of hyperinsulinemia in obese women with abdominal body fat distribution. Metabolism 41 (1992) 763-767
111. Genazzani A.R., Gastaldi M., Bidzinska B., Mercuri N., Genazzani A.D., Nappi R.E., et al. The brain as a target organ of gonadal steroids. Psychoneuroendocrinology 17 (1992) 385-390
112. Bernasconi S., Petraglia F., Iughetti L., Marcellini C., Lamborghini A., Faccinetti F., et al. Impaired beta-endorphin response to human corticotropin-releasing hormone in obese children. Acta Endocrinol 119 (1988) 7-10
113. Facchinetti F., Liveri C., Petraglia F., Cortona L., Severi F., and Genazzani A.R. Dexamethasone fails to suppress hyperendorphinemia of obese children. Acta Endocrinol 116 (1987) 90-94
114. Balsamo A., et al. Endocrine aspects of pediatric obesity. In: Giorgi P.L., Suskind R.M., and Catassi C. (Eds). Pediatric and adolescent medicine (1992), Karger, Basel 59-68
115. Maffeis C., Micciolo R., Zaffanello M., and Pinelli L. Basal energy expenditure in obese and normal weight schoolchildren. Acta Paediatr Scand 80 (1991) 1145-1149
116. Giugliano D., Cozzolino D., Torella R., Lefebvre P.J., Franchimont P., and D'Onofrio F. Persistance of altered metabolic responses to beta-endorphin after normalization of body weight in human obesity. Acta Endocrinol 124 (1991) 159-165
117. Getto C.J., Fullerton D.T., and Carlson I.H. Plasma immunoreactive endorphin response to glucose ingestion in human obesity. Appetite 5 (1984) 329-334
118. Giovannini C., Ciucci E., Clementi R., Cugini P., Facchinetti F., and Negri M. β-Endorphin, insulin, ACTH and cortisol plasma levels during oral glucose tolerance test in obesity after weight loss. Horm Metab Res 2 (1990) 96-100
119. Drewnowski A., Krahn D.D., Demitrack M.A., Nairn K., and Gosnell B.A. Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiol Behav 51 (1992) 371-379
120. Komaki G., Tamai H., Sumioki H., Mori T., Kobayashi N., Mori K., et al. Plasma beta-endorphin during fasting in man. Horm Res 33 (1990) 239-243
121. Baile C.A., McLaughlin C.L., and Della-Fera M.A. Role of cholecystokinin and opioid peptides in control of food intake. Physiol. Rev 66 (1986) 172-234
122. Sipols A.J., Baskin D.G., and Schwartz M.W. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic gene expression. Diabetes 249 (1995) 546-549
123. Bertino M., Beauchamp G.K., and Engelman K. Naltrexone, an opioid blocker, alters taste perception and nutrient intake in human. Am J Physiol 261 (1991) R59-R63
124. Dum J., Gramsch C., and Herz A. Activation of hypothalamic betaendorphin pools by reward induced by highly palatable food. Pharmacol Biochem Behav 18 (1983) 443-447
125. Melchior J.C., Rigaud D., Colas-Linhart N., Petiet A., Girard A., and Apfelbaum M. Immunoreactive Beta-endorphin increases after an aspartame chocolate drink in healthy human subject. Physiol Behav 50 (1991) 941-944
126. Moran L.J., Noakes M., Clifton P.M., Wittert G.A., Tomlinson L., Galletly C., et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab 89 (2004) 3337-3344
127. Morley J.E., and Levine A.S. The role of the endogenous opiates as regulators of appetite. Am J Clin Nutr 35 (1982) 757-761
128. Poretsky L., Cataldo N.A., Rosenwaks Z., and Giudice L.C. The insulin related ovarian regulatory system in health and disease. Endocr Rev 20 (1999) 535-582
129. Pasquali R., and Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 39 (1993) 1-16
130. Arora S. Role of neuropeptides in appetite regulation and obesity-a review. Neuropeptides 40 (2006) 375-401
131. Barbieri R.L., Smith S., and Ryan J. The role of hyperandrogenemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 50 (1988) 197-210
132. Frager M.S., Pieper D.R., Tonetta S.A., Duncan J.A., and Marshall J.C. Effects of castration, steroid replacement and the role of gonadotropin-releasing hormone in modulating receptors in the rat. J Clin Invest 67 (1981) 615-623
133. Pasquali R., and Vicennati V. Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int J Obes Relat Metab Disord 24 (2000) S47-S49
134. Hadziomerović D., Rabenbauer B., and Wildt L. Normalization of hyperinsulinemia by chronic opioid receptor blockade in hyperandrogenemic women. Fertil Steril 86 (2006) 651-657
135. Fulghesu A.M., Ciampelli M., Fortini A., Cucinelli F., Guido M., Caruso A., et al. Effect of opioid blockade on insulin metabolism in polycystic ovarian disease. Hum Reprod 10 (1995) 2253-2257
136. Guido M., Pavone V., Ciampelli M., Murgia F., Fulghesu A.M., Apa R., et al. Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome. J Clin Endocrinol Metab 83 (1998) 1742-1745
137. Soules M.R., Steiner R.A., Clifton D.K., Cohen N.L., Aksel S., and Bremner W.J. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab 58 (1984) 378-383
138. Berga S.L., and Yen S.S.C. Opioidergic regulation of LH pulsatility in women with PCOS. Clin Endocrinol 30 (1989) 1989
139. Petraglia F., Locatelli V., Penalva A., Cocchi D., Genazzani A.R., and Müller E.E. Gonadal steroid modulation of naloxone-induced LH secretion in the rat. J Endocrinol 101 (1984) 33-39
140. Barkan A., Regiani S., Duncan J., Papavasiliou S., and Marshall J.C. Opioids modulate pituitary receptors for gonadotropin-releasing hormone. Endocrinology 112 (1983) 387-389
141. Xia Y.X., Weiss J.M., Polack S., Diedrich K., and Ortmann O. Interactions of insulin-like growth factor-I, insulin and estradiol with GnRH-stimulated luteinizing hormone release from female rat gonadotrophs. Eur J Endocrinol 144 (2001) 73-79
142. Lawson M.A., Jain S., Sun S., Patel K., Malcolm P.J., and Chang R.J. Evidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women. J Clin Endocrinol Metab 93 (2008) 2089-2096
143. Patel K., Coffler M.S., Dahan M.H., Yoo R.Y., Lawson M.A., Malcom P.J., et al. Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. J Clin Endocrinol Metab 88 (2003) 5456-5461
144. Poretsky L., Cataldo N.A., Rosenwaks Z., and Giudice L.C. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20 (1999) 535-582
145. Nestler J.E. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 15 (1997) 111-122
146. Garmes H.M., Tambascia M.A., and Zantut-Wittmann D.E. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecol Endocrinol 21 (2005) 317-323
147. Vrbíková J., Hill M., Stárka L., Cibula D., Bendlová B., Vondra K., et al. The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. Eur J Endocrinol 144 (2001) 619-628
148. Moghetti P., Castello R., Negri C., Tosi F., Perrone F., Caputo M., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. Clin Endocrinol Metab 85 (2000) 139-146
149. Eagleson C.A., Gingrich M.B., Pastor C.L., Arora T.K., Burt C.M., Evans W.S., et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the GnRH pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 85 (2000) 4047-4052
150. Mehta R.V., Patel K.S., Coffler M.S., Dahan M.H., Yoo R.Y., Archer J.S., et al. Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment. J Clin Endocrinol Metab 90 (2005) 2136-2141
151. Blank S.K., McCartney C.R., and Marshall J.C. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod Update 12 (2006) 351-361
152. Lanzone A., Fulghesu A.M., Cucinelli F., Ciampelli M., Caruso A., and Mancuso S. Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion. J Clin Endocrinol Metab 80 (1995) 3501-3506
153. Roozenburg B.J., van Dessel H.J., Evers J.L., and Bots R.S. Successful induction of ovulation in normogonadotrophic clomiphene resistant anovulatory women by combined naltrexone and clomiphene citrate treatment. Hum Reprod 12 (1997) 1720-1722
154. Fruzzetti F., Bersi C., Parrini D., Ricci C., and Genazzani A.R. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril 77 (2002) 936-944
155. Ahmed M.I., Duleba A.J., El Shahat O., Ibrahim M.E., and Salem A. Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome. Hum Reprod (2008) (in press)
156. Chrousos G.P., and Gold P.W. The concepts of stress and stress system disorders. J Am Med Assoc 267 (1992) 1244-1252
157. Turi A., Di Prospero F., Mazzarini A., Costa M., Cignitti M., and Garzetti G.G. Lymphocytes subset in hyperandrogenic women with polycystic ovarian disease. Acta Eur Fertil 19 (1988) 155-157
158. Amato G., Conte M., Mazziotti G., Lalli E., Vitolo G., and Tucker A.T. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 101 (2003) 1177-1182
159. Gallinelli A., Ciaccio I., Gianella L., Salvatori M., Marsella T., and Volpe A. Correlations between concentrations of interleukin-12 and interleukin-13 and lymphocyte subset in the follicular fluid of women with and without polycystic ovary syndrome. Fertil Steril 79 (2003) 1365-1372
160. Mörch H., and Pedersen B.K. β-Endorphin and the immune system-possible role in autoimmune diseases. Autoimmunity 21 (1995) 161-171
161. Sharp B.M., McAllen K., Gekker G., Shahabi N.A., and Peterson P.K. Immunofluorescence detection of delta opioid receptors (DOR) on human peripheral blood CD4+ T cells and DOR-dependent suppression of HIV-1 expression. J Immunol 167 (2001) 1097-1102
162. Sharp B., and Linner K. What do we know about the expression of proopiomelanocortin transcripts and related peptides in lymphoid tissue?. Endocrinology 133 (1993) 1921A-B
163. O'Hare E., Shaw D.L., Tierney K.J., Kim E.-M., Levine A.S., and Shephard R.A. Behavioral and neurochemical mechanisms of the action of mild stress in the enhancement of feeding. Behav Neurosci 118 (2004) 173-177
164. Drolet G., Dumont E.C., Gosselin I., Kinkead R., Laforest S., and Trottier J.F. Role of endogenous opioid system in the regulation of the stress response. Prog Neuropsychopharmacol Biol Psychiatry 25 (2001) 729-741
165. Kreek M.J., and Koob G.F. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 51 (1998) 23-47
166. Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Bailliere Clin Endocrinol Metab 10 (1996) 221-247
167. Bjorntorp P. Adipose tissue distribution and function. Int J Obes 15 (1991) 67-81
168. Rasgon N.L., Rao R.C., Hwang S., Altshuler L.L., Elman S., Zuckerbrow-Miller J., et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 74 (2003) 299-304
169. Trent M.E., Rich M., Austin S.B., and Gordon C.M. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med 156 (2002) 556-560
170. Weiner C.L., Primeau M., and Ehrmann D.A. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med 66 (2004) 356-362
171. Hahn S., Janssen O.E., Tan S., Pleger K., Mann K., Schedlowski M., et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 153 (2005) 853-860
172. Hollinrake E., Abreu A., Maifeld M., Van Voorhis B.J., and Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 87 (2007) 1369-1376
173. Hahn S., Janssen O.E., Tan S., Pleger K., Mann K., Schedlowski M., et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 153 (2005) 853-860
174. Barnard L., Ferriday D., Guenther N., Strauss B., Balen A.H., and Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod 22 (2007) 2279-2286
175. Kennedy S.E., Koeppe R.A., Young E.A., and Zubieta J.K. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 63 (2006) 1199-1208
176. Kamboj S.K., Tookman A., Jones L., and Curran H.V. The effects of immediate-release morphine on cognitive functioning in patients receiving chronic opioid therapy in palliative care. Pain 117 (2005) 388-395
177. Hebb A.L., Poulin J.F., Roach S.P., Zacharko R.M., and Drolet G. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 1225-1238
178. Schattmann L., and Sherwin B.B. Effects of the pharmacologic manipulation of testosterone on cognitive functioning in women with polycystic ovary syndrome: a randomized, placebo-controlled treatment study. Horm Behav 51 (2007) 579-586
179. Schattmann L., and Sherwin B.B. Testosterone levels and cognitive functioning in women with polycystic ovary syndrome and in healthy young women. Horm Behav 51 (2007) 587-596
180. Vgontzas A.N., Trakada G., Bixler E.O., Lin H.M., Pejovic S., Zoumakis E., et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 86 (2001) 517-520
181. Tasali E., Van Cauter E., and Ehrmann A.D. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 36-42
182. Emukhvari N.M., Rukhadze I.R., Mgaloblishvili M.M., Chidzhavadze E.O., and Babilodze M.R. The role of opioid system in the regulation of the sleep wakefulness cycle. Zh Vyssh Nerv Deiat Im I P Pavlova 55 (2005) 100-109